What is the 13F Pro Quality Score for CGON?

13F Pro ranks CG Oncology, Inc. (CGON) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CGON's current score at https://13fpro.ai/research/CGON (free sign-up required for the full ranking).

Where does 13F Pro source CGON data?

All CG Oncology, Inc. fundamentals and ownership data come directly from SEC EDGAR. CG Oncology, Inc. files with the SEC under CIK 1991792. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CGON in?

CG Oncology, Inc. (CGON) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CGON research updated on 13F Pro?

CGON's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CG Oncology, Inc.(CGON)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1991792 CGON stock profile & AI dashboard →

13F Pro Quality Score

28.0/100

Rank #2,455 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

99.1/100

Profitability

0.8/100

Balance Sheet

10.4/100

Earnings Quality

30.0/100

Free Cash Flow

0.6/100

Institutional Flow

92.5/100

Revenue Scale

1.2/100

Dilution Risk

0.9/100

CGON Stock Analysis & AI Quality Score

AI stock analysis and institutional research for CG Oncology, Inc. (CGON), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CGON at 28.0/100 on a 32-signal composite quality model, placing it at rank #2,455 of 2,879 stocks — the bottom half of the AI-ranked universe. CGON scores in the top quartile across revenue growth (99.1), institutional flow (92.5). Areas of concern include free cash flow (0.6) and profitability (0.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), CG Oncology, Inc. reports quarterly revenue of $1.1M, net income of $-60.2M, free cash flow of $-57.2M. Top institutional holders of CGON by reported 13-F value include RTW INVESTMENTS,, Decheng Capital, WELLINGTON MANAGEMENT GROUP LLP, based on the most recent SEC filings. CGON trades on the Nasdaq exchange and files with the SEC under CIK 1991792. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CGON daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CG Oncology, Inc. directly from SEC EDGAR. CG Oncology, Inc.'s 13F Pro composite quality score has ranged between 8 and 76 since 2026, currently 28.0 — an improving long-term trajectory across 36 quarterly and live scoring snapshots.

Revenue

Q1 2026

$1.1M

Net Income

Q1 2026

$-60.2M

Free Cash Flow

Q1 2026

$-57.2M

D/E Ratio

Q1 2026

0.00

AI Insight: CGON Financial Trends

CG Oncology remains pre-commercial with zero product revenue through Q4 2025, while quarterly cash burn accelerated sharply to $57M in Q1 2026.

• Operating losses widened from -$26M in Q2 2024 to -$66M in Q1 2026, a 154% deterioration over seven quarters.

• Operating cash outflow surged to -$57M in Q1 2026 from -$16M in Q2 2024, reflecting rapidly escalating spend.

• Equity jumped to $1,092M in Q1 2026 from $753M in Q4 2025, suggesting a meaningful capital raise.

• Token revenue of $2M appeared in Q3 2025 and Q4 2025 before dipping to $1M in Q1 2026 — nascent and inconsistent.

⚠ At $57M quarterly cash burn in Q1 2026, runway duration is the critical variable — monitor equity raises closely.

⚠ Revenue remains effectively zero; any sustained commercial inflection from ongoing trials would be a key positive catalyst.

⚠ Total debt appeared at $3M in Q3 2025 and held flat — minimal leverage risk for now, but worth tracking.

AI Insight: CGON Ratio Trends

CGON's capital returns remain deeply negative, though ROIC has partially recovered from a Q3 2025 trough of -29.6% to -24.3% in Q1 2026.

• ROE deteriorated steadily from -13.7% in Q2 2024 to a trough of -25.5% in Q3 2025, signaling accelerating equity erosion.

• ROIC worsened from -18.7% in Q2 2024 to -29.6% in Q3 2025, reflecting deepening capital inefficiency over five quarters.

• ROIC improved from -29.6% in Q3 2025 to -24.3% in Q1 2026, a partial but meaningful recovery over two quarters.

• D/E ratio stands at 0.00 in Q1 2026, indicating CGON carries no debt — preserving financial flexibility.

⚠ ROE and ROA remain deeply negative (-22.1%, -21.2% in Q1 2026) — sustained losses will erode the equity base over time.

⚠ Whether the ROIC recovery from the Q3 2025 trough (-29.6%) continues, or reverses as cash burn persists.

⚠ OpMargin and NPM data are entirely absent — inability to assess operating leverage or path to profitability.

Get alerted when CGON's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CG Oncology, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CGON

RTW INVESTMENTS, LP
$472.7M6,984,808 sh
Decheng Capital LLC
$431.2M6,371,669 sh
WELLINGTON MANAGEMENT GROUP LLP
$363.5M5,371,232 sh
BlackRock, Inc.
$342.7M5,064,180 sh
FMR LLC
$254.8M3,764,844 sh
TCG Crossover Management, LLC
$248.4M3,670,206 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$209.5M3,095,098 sh
VANGUARD CAPITAL MANAGEMENT LLC
$205.3M3,033,625 sh
STATE STREET CORP
$179.2M2,647,054 sh
Foresite Capital Management VI LLC
$150.3M2,221,474 sh

Fund	Value	Shares
RTW INVESTMENTS, LP	$472.7M	6,984,808
Decheng Capital LLC	$431.2M	6,371,669
WELLINGTON MANAGEMENT GROUP LLP	$363.5M	5,371,232
BlackRock, Inc.	$342.7M	5,064,180
FMR LLC	$254.8M	3,764,844
TCG Crossover Management, LLC	$248.4M	3,670,206
VANGUARD PORTFOLIO MANAGEMENT LLC	$209.5M	3,095,098
VANGUARD CAPITAL MANAGEMENT LLC	$205.3M	3,033,625
STATE STREET CORP	$179.2M	2,647,054
Foresite Capital Management VI LLC	$150.3M	2,221,474

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CGON on your watchlist

Track score changes the day CG Oncology, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CGON a good stock to buy?

13F Pro's AI-powered analysis of CG Oncology, Inc. (CGON) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CGON are available on the CGON stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CGON?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CGON. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CG Oncology, Inc.'s investment landscape.